David E. Mery

Postdoctoral Fellow

UAMS

Last publication 2025 Last refreshed 2026-05-23

postdoc

7 h-index 31 pubs 175 cited

Research Areas

Links

ORCID Research Group

OverviewAI-generated summary

David E. Mery's research focuses on multiple myeloma and its precursor stages, investigating the underlying molecular mechanisms and potential therapeutic targets. His work has explored the immune microenvironment in multiple myeloma, identifying alterations that may contribute to disease progression. Mery has contributed to the development of prognostic scoring systems for patients with newly diagnosed multiple myeloma, aiming to improve risk stratification. He has also examined specific molecular markers, such as NEK2 expression in myeloid progenitors, and their impact on T-cell immunity in the context of multiple myeloma. His research includes the study of chimeric antigen receptor (CAR) T-cell therapies, specifically bispecific CAR-T cells targeting BCMA and CD24, for controlling multiple myeloma growth. Mery's scholarship includes 31 publications with 160 citations and an h-index of 7. He has a history of collaboration with researchers at the University of Arkansas for Medical Sciences, including John D. Shaughnessy Jr., Fumou Sun, Visanu Wanchai, and Clyde Bailey, with whom he shares multiple publications.

Metrics

h-index: 7
Publications: 31
Citations: 175

Selected Publications

Gene Expression–Based prediction of 1q, 1p, 13q, and 17p chromosome ploidy in newly diagnosed and paired relapsed myeloma and across the plasma cell dyscrasia spectrum (2025)

DOI OpenAlex
Polyclonal plasma cell (PolyPC) signature as a key indicator for predicting the progression of MGUS to multiple myeloma (2025)

1 citation DOI OpenAlex
Targeting caseinolytic mitochondrial matrix peptidase, a novel contributor to the pathobiology of high-risk multiple myeloma (2025)

5 citations DOI OpenAlex
Single-cell analysis of neoplastic plasma cells identifies myeloma pathobiology mediators and potential targets (2025)

3 citations DOI OpenAlex
Identification of Risk Factors for Myeloma Progression in African American Patients (2024)

DOI OpenAlex
The Low-Bone (LB) Subtype of Multiple Myeloma Exhibits an Inferior Outcome in African Americans (2024)

DOI OpenAlex
Multi-Omics Reveal Immune Microenvironment Alterations in Multiple Myeloma and Its Precursor Stages (2024)

1 citation DOI OpenAlex
The Role of CST6 in Immunosuppression in the Multiple Myeloma Microenvironment (2024)

DOI OpenAlex
Multi-omics reveal immune microenvironment alterations in multiple myeloma and its precursor stages (2024)

22 citations DOI OpenAlex
A Risk Stratification System in Myeloma Patients with Autologous Stem Cell Transplantation (2024)

4 citations DOI OpenAlex
Prognostic value of ferritin in ASCT MM patients: integration with GEP models and ISS series systems (2024)

7 citations DOI OpenAlex
Development and validation of an individualized and weighted Myeloma Prognostic Score System (<scp>MPSS</scp>) in patients with newly diagnosed multiple myeloma (2024)

17 citations DOI OpenAlex
Bispecific BCMA/CD24 CAR-T cells control multiple myeloma growth (2024)

33 citations DOI OpenAlex
High NEK2 expression in myeloid progenitors suppresses T cell immunity in multiple myeloma (2023)

17 citations DOI OpenAlex
Application of R2-ISS risk stratification to patients with multiple myeloma treated with autologous stem cell transplants at UAMS (2023)

11 citations DOI OpenAlex